Jill Hazelbaker, President and Chief Corporate Affairs Officer of Uber Technologies, Inc. (NYSE:UBER), filed a Form 4 on September 18, 2026, reporting restricted stock unit vesting transactions that occurred on September 16, 2026.
Andrew Macdonald, President and Chief Operating Officer of Uber Technologies, Inc. (NYSE:UBER), filed a Form 4 on September 18, 2026, reporting restricted stock unit conversions and tax-related share disposals that occurred on September 16, 2026.
Ian Steward, Chief Revenue Officer of GitLab Inc. (NASDAQ:GTLB), filed a Form 4 on September 18, 2026, disclosing a transaction in Class A Common Stock dated September 16, 2026.
A Form 4 filed on September 18, 2026 discloses that Sivaprasad Padisetty, Chief Technology Officer of GitLab Inc. (NASDAQ:GTLB), disposed of 30,888 shares of Class A Common Stock on September 16, 2026 to satisfy tax obligations arising from the vesting of a restricted stock …
Jessica P. Ross, Chief Financial Officer of GitLab Inc., filed a Form 4 on September 18, 2026, reporting the disposition of 32,628 shares of Class A Common Stock on September 16, 2026, to satisfy tax obligations arising from the vesting of a restricted stock …
A Form 4 filed with the SEC on September 18, 2026 discloses that Laura Alber, President and CEO of Williams-Sonoma, Inc. (NYSE:WSM), sold a total of 35,000 shares of common stock on September 16, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
Jeffrey Howie, Executive Vice President and Chief Financial Officer of Williams Sonoma Inc (NYSE:WSM), disclosed the sale of 3,045 shares of common stock on September 16, 2026, in a statement of changes in beneficial ownership filed with the SEC on September 18, 2026.
Jenna Rozenblat, President of Real REMAX Group Inc. (NASDAQ:REAX), filed a Form 4 on September 18, 2026, disclosing a restricted stock unit vesting event that occurred on September 17, 2026.
Alexandra Lumpkin, Chief Legal Officer of Real REMAX Group Inc. (NASDAQ:REAX), filed a Form 4 on September 18, 2026, disclosing transactions in restricted stock units that occurred on September 17, 2026.
Theravance Biopharma, Inc. filed a Form 8-K on September 18, 2026, reporting the voting results from its extraordinary general meeting held that same day, at which shareholders approved a merger agreement with Zymeworks Inc.